The Combined Clinical Diagnosis of TNF-, TSH, and p185 Protein in Breast Cancer.

OBJECTIVE

To study the concentrations of tumor necrosis factor (TNF-), thyroid-stimulating hormone (TSH), and c-erbB-2 oncogene protein product P185 in different pathological stages of breast cancer and to analyze their combined clinical diagnosis of breast cancer significance.

METHODS

67 breast cancer patients who were treated in our hospital from January 2018 to September 2020 were set as the breast cancer group and were divided into stages I, II, III, and IV according to clinicopathology. In addition, 55 patients with benign breasts who were admitted to the hospital at the same time were selected as the benign breast group, and 60 healthy people in our hospital during the same period were selected as the healthy group. The differences between serum TNF-, TSH, and p185 protein positive rate in 3 groups and the levels of TNF- and TSH and p185 protein positive rate in patients with different pathological characteristics were compared and analyzed, and the differences between the combined detection and the single detection were analyzed.

RESULTS

Compared with the benign breast group and the healthy group, the serum levels of TNF- (44.61 ± 12.54 versus 29.75 ± 10.19 versus 56.87 ± 15.36 versus 102.37 ± 15.36), TSH (0.98 ± 0.13 versus 0.94 ± 0.17 versus 1.17 ± 0.24 versus 1.22 ± 0.15) and p185 protein positive rate were higher in the I-II and III-IV groups, and the difference was statistically significant ( < 0.05). TNF- detection sensitivity was 44.74%, specificity was 62.06%, which was higher than p185 sensitivity of 31.01%, specificity of 49.78%, higher than TSH sensitivity of 27.51%, specificity of 39.77%. At the same time, the sensitivity and specificity of combined detection of TNF-, TSH, and p185 protein were 67.35% and 70.41%, which were significantly higher than the sensitivity and specificity of single detection, and the difference was statistically significant ( < 0.05).

CONCLUSION

TNF-, TSH, and p185 protein are expected to be used as auxiliary basis for diagnosis in the future. But in general, the serum indexes in this study had low sensitivity and specificity for the diagnosis of breast cancer, which limited their diagnostic function in clinical use.